Physician profile
Rene Casanova
NPI 1689646440
$1,119.08
in general payments reported to CMS, 2019-2025
21 companies · $466 in 2025
The $466 reported for 2025 was more than what 83% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.52 · 2020: $88.99 · 2022: $87.40 · 2023: $24.08 · 2024: $429 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.90 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $186.29 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $174.57 | 2025 | Ozempic, Rybelsus, Wegovy |
| Saluda Medical Americas, INC. | $79.39 | 2024 | Evoke |
| Genentech USA, INC. | $79.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.29 | 2024-2025 | Jardiance |
| Abbott Laboratories | $70.21 | 2022-2023 | Freestyle Libre 2 |
| Exact Sciences Corporation | $62.03 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $55.34 | 2024-2025 | Mounjaro, Zepbound |
| Amgen INC. | $53.29 | 2024-2025 | Otezla, Repatha, Otezla |
| Corcept Therapeutics | $43.82 | 2024-2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $37.90 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $35.69 | 2024-2025 | Zoryve |
| Pfizer INC. | $24.64 | 2024 | |
| Dexcom, INC. | $23.56 | 2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $20.43 | 2024 | Omnipod |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $18.84 | 2024 | Nexletol |
| Ibsa Pharma INC. | $18.79 | 2020 | |
| Viiv Healthcare Company | $17.53 | 2024 | Apretude |
| Glaxosmithkline, LLC. | $14.46 | 2020 | |
| Mannkind Corporation | $14.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Casanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.